Adverse events ( · people with a primary brain tumour
It is very uncertain whether boele 2013: modafinil changes adverse events ( compared with placebo (very low certainty).
1 finding from 1 review
Fatigue · people with a primary brain tumour
2 findings from 1 review
Cognition Trail Making Test A · people with a primary brain tumour
1 finding from 1 review
Cognition Trail Making Test B · people with a primary brain tumour
1 finding from 1 review
Heart failure · adults with cancer receiving anthracyclines
Dexrazoxane probably leads to lower clinical heart failure Available case analysis compared with no cardioprotective intervention or placebo (moderate certainty).
1 finding from 1 review
Secondary malignant neoplasms · adults with cancer receiving anthracyclines
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical heart failure and subclinical myocardial dysfunction combined Comparable definitions; see Characteristics of included studies for exact definitions. Available‐case analysis · adults with cancer receiving anthracyclines
Dexrazoxane probably leads to lower clinical heart failure and subclinical myocardial dysfunction… compared with no cardioprotective intervention or placebo (moderate certainty).
2 findings from 1 review
Overall survival (Illustrative comparative risks reported as number of alive participants) · adults with cancer receiving anthracyclines
Dexrazoxane showed no clear difference in overall survival (Illustrative comparative risks reported as number… compared with no cardioprotective intervention or placebo (moderate certainty).
1 finding from 1 review
Progression‐free survival · adults with cancer receiving anthracyclines
Dexrazoxane may leads to lower progression‐free survival Defined as time from first date of… compared with no cardioprotective intervention or placebo (low certainty).
3 findings from 1 review
Partial response (partial or complete response) · adults with cancer receiving anthracyclines
Dexrazoxane showed no clear difference in tumour response rate Defined as number of complete or partial… compared with no cardioprotective intervention or placebo (moderate certainty).
1 finding from 1 review
Quality of life · adults with cancer receiving anthracyclines
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Rate of spontaneous voiding recovery 1 week after surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time after surgery to post‐void residual volume of urine ≤ 50 mL (days)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Post‐void residual urine volume (mL) at 1 month after surgery
1 finding from 1 review
Urinary tract infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Subjective urinary symptoms
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific adverse events: serious haemorrhage · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serious haemorrhage compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review
Specific adverse events: serious thromboembolic events · women with persistent, recurrent, or metastatic cervical cancer
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serious thromboembolic events compared with placebo plus chemotherapy (very low certainty).
1 finding from 1 review